Inventor · disambiguated record
Max Hasmann
Also filed as: HASMANN MAX
13 granted patents·16 pending applications·254 citations·filing 1998–2017
93Inventor score
Files withHOFFMANN LA ROCHE8KLINGE CO CHEM PHARM FAB7FRIESS THOMAS6ASTELLAS DEUTSCHLAND GMBH3ASTELLAS PHARMA GMBH3
Top patents by PatentIndex Score
29 records- 0193US6903118B1Piperazinyl-substituted pyridylalkane, alkene and alkine carboxamidesKLINGE CO CHEM PHARM FAB·Filed 2000·Granted Jun 7, 2005·50 cites·29 claims
- 0292US8529901B2Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence labelHASMANN MAX·Filed 2008·Granted Sep 10, 2013·19 cites·2 claims
- 0391US9687568B2Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence labelHOFFMANN LA ROCHE·Filed 2013·Granted Jun 27, 2017·14 cites·23 claims
- 0491US6593344B1Piperadinyl-substituted pyridylalkane, alkene and alkine carboxamidesKLINGE CO CHEM PHARM FAB·Filed 2000·Granted Jul 15, 2003·41 cites·29 claims
- 0591US6451816B1Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppressionKLINGE CO CHEM PHARM FAB·Filed 1998·Granted Sep 17, 2002·62 cites·18 claims
- 0688US9180185B2Combination therapy of anti-HER3 antibodiesHOFFMANN LA ROCHE·Filed 2014·Granted Nov 10, 2015·13 cites·15 claims
- 0787US9090700B2Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2FRIESS THOMAS·Filed 2010·Granted Jul 28, 2015·13 cites·9 claims
- 0885US6506572B2Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapyKLINGE CO CHEM PHARM FAB·Filed 2001·Granted Jan 14, 2003·18 cites·25 claims
- 0977US7320993B1Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agentsASTELLAS DEUTSCHLAND GMBH·Filed 2000·Granted Jan 22, 2008·10 cites·18 claims
- 1070US7276524B2Pyridyl alkane acid amides as cytostatics and immunosuppressivesASTELLAS DEUTSCHLAND GMBH·Filed 2003·Granted Oct 2, 2007·4 cites·29 claims
- 1162US6444823B1Pyridyl alkane acid amides as cytostatics and immunosuppressivesKLINGE CO CHEM PHARM FAB·Filed 1998·Granted Sep 3, 2002·8 cites·15 claims
- 1262US2018251536A1Tumor therapy with an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 1360US7241745B2Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressivesASTELLAS PHARMA GMBH·Filed 2002·Granted Jul 10, 2007·1 cites·9 claims
- 1460US2008050385A1Tumor therapy with an anti-vegf antibodyFRIESS THOMAS·Filed 2007·Application pending·0 cites
- 1557US2007224203A1Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2FRIESS THOMAS·Filed 2007·Application pending·0 cites
- 1657US2007142377A1Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and ImmunosuppressivesBIEDERMANN ELFI·Filed 2007·Application pending·0 cites
- 1757US2017239353A1Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2HOFFMANN LA ROCHE·Filed 2017·Application pending·0 cites
- 1857US2011223159A1Tumor therapy with an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2011·Application pending·0 cites
- 1957US2013183292A1Tumor therapy with an anti-vegf antibodyFRIESS THOMAS·Filed 2012·Application pending·0 cites
- 2055US2015239969A1Tumor therapy with an anti-vegf antibodyHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 2154US7192967B1Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agentsASTELLAS PHARMA GMBH·Filed 2000·Granted Mar 20, 2007·1 cites·24 claims
- 2253US2007219197A1Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressivesASTELLAS PHARMA GMBH·Filed 2006·Application pending·0 cites
- 2351US2015283238A1Tumor Therapy with an Antibody for Vascular Endothelial Growth Factor and an Antibody for Human Epithelial Growth Factor Receptor Type 2HOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 2451US2010285010A1Tumor therapy with an anti-vegf antibodyFRIESS THOMAS·Filed 2010·Application pending·0 cites
- 2544US2008102069A1Tumor therapy with a combination of anti-her2 antibodiesFRIESS THOMAS·Filed 2007·Application pending·0 cites
- 2644US2004009967A1Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immuno-suppressivesKLINGE CO CHEM PHARM FAB·Filed 2002·Application pending·0 cites
- 2741US2004029861A1Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppressionKLINGE CO CHEM PHARM FAB·Filed 2002·Application pending·0 cites
- 2841US2016159912A1Combination therapy of anti-her3 antibodiesHOFFMANN LA ROCHE·Filed 2015·Application pending·0 cites
- 2934US2010227896A1Use of vitamin pp compoundsASTELLAS DEUTSCHLAND GMBH·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Max Hasmann files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →